September 2024 – Jacksonville, US – Lindo Life Science, a division of Lindo Technology Group, is proud to announce the establishment of a know-how license agreement with Mayo Clinic. This collaboration aims to develop a groundbreaking endotracheal tube embedded with antimicrobial blue light technology, intended to significantly reduce instances of ventilator-associated pneumonia (VAP).
Working closely with esteemed clinicians at Mayo Clinic in Jacksonville, Florida, Lindo Life Science’s dedicated team aims to produce a proof of concept for this innovative medical device. The new endotracheal tube is designed to harness the power of antimicrobial blue light to eliminate harmful bacteria, thus aiming to lower the risk of VAP in patients requiring mechanical ventilation.
Robert Gangi, CEO and Founder of Lindo Life Science, expressed optimism about the collaboration, stating, “Collaborations like this are crucial for the successful translation of innovative ideas into practical medical solutions. We believe that we can provide the ideal foundation to develop a medical device with the potential to revolutionise the prevention of VAP.”
Key highlights of the collaboration:
- Objective: Reduce instances of ventilator-associated pneumonia (VAP) using antimicrobial blue light technology.
- Technology: Development of an endotracheal tube that integrates antimicrobial blue light to eliminate harmful bacteria.
- Collaboration: Working with Mayo Clinic to leverage their clinical expertise and Lindo Life Science’s technological innovation.
- Impact: Enhanced patient outcomes through the reduction of VAP-related complications.
This initiative aligns with Lindo Life Science’s mission to advance medical technology solutions that improve patient care and safety. It also underscores the company’s commitment to fostering strategic collaborations that drive innovation and deliver tangible healthcare benefits.